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Abstract
The European Reference Network for rare liver diseases (ERN RARE-LIVER) is a Europe-wide network of paediatric
and adult hepatologists from expert centres in close collaboration with patient advocates from the various disease-
areas covered in our ERN. The ERN is focused on providing more equitable care across Europe and creates a
network of both medical specialists and patient experts in rare liver disease. This position paper summarizes the
achievements of the first year and plots the route for the near future for ERN RARE-LIVER, as discussed during a strategy
meeting that took place 27 and 28 February 2018 in Nijmegen, the Netherlands. ERN RARE-LIVER has established itself
as a group with experts, hospitals and patients. One of the tools to improve communication is the clinical patient
management system (CPMS) that allows access to expert consultation by European physicians confronted with a
patient with rare liver disease. ERN RARE-LIVER will function as the platform to improve healthcare by initiating
registries, foster research efforts and coordinate development of clinical guidelines in Europe.
Keywords: European reference network, ERN, Rare liver disease, Autoimmune liver disease, Paediatric liver disease,
Structural liver disease
Background
European Reference Networks (ERN) for rare diseases
(Fig. 1) have been initiated by the European Commission
as a means to achieve equitable care for rare diseases
across Europe [1]. The ERN programme started in earn-
est in 2017 with the establishment of 24 ERNs within a
European legal framework dedicated to rare or low
prevalence complex diseases. This brought together
more than 300 health care providers (hospitals) and 900
expert teams. The novelty of the programme offers a
certain degree of freedom (and uncertainty) with respect
to path and direction to take [2]. The vision of the estab-
lishment of ERNs was to realize more equitable access
to the best healthcare across Europe and to drive
improvement of standard of care and clinical knowledge
of rare diseases in Europe. Working closely with the
clinical centres, physicians and patients, the ERN must
disseminate best clinical practice, use innovative IT solu-
tions to enable clinicians to access expert knowledge
across Europe, update clinical guidelines to enable
standardisation of care and to provide patients with rele-
vant high quality information.
ERN RARE-LIVER
The European Reference Network for rare liver diseases
(ERN RARE-LIVER) has been established as a Europe-
wide network of paediatric and adult hepatologists from
expert centres with the aim to improve clinical manage-
ment and research of rare liver disease in adults and
children. The ERN currently covers paediatric and adult
care for 12 different rare liver disorders, distributed over
three pillars (Fig. 2). Pillar 1 (autoimmune liver disease)
includes primary biliary cholangitis (PBC), autoimmune
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hepatitis (AIH), primary sclerosing cholangitis (PSC) and
IgG4 disease. Pillar 2 (metabolic, biliary atresia and re-
lated diseases) includes alpha-1 anti-trypsin disease, Wil-
son’s disease, genetic cholestatic disease, biliary atresia
and choledochal cysts. Pillar 3 (structural liver disease)
includes polycystic liver disease (PLD) and other cystic
liver disease, intrahepatic cholangiocarcinoma and vas-
cular liver disease.
The ERN RARE-LIVER consists of 28 expert centres,
and is gradually expanding (Additional file 1). Key to the
success of ERN RARE-LIVER is close collaboration with
patient organizations and groups, at the moment num-
bering 37.
There is an unmet need in the arena of rare liver dis-
orders. Most rare liver disorders are infrequent and ex-
pertise is concentrated in few centres. Expert knowledge
of rare liver diseases is scattered, concentrated with a
few experts, takes many years to accumulate, and is
bound to core facilities that allow knowledge building.
Patients with rare diseases do not necessarily live close
to an expert centre, certainly not when seen on a Euro-
pean scale. The vision of ERN RARE-LIVER is that pa-
tients with a rare liver disease deserve access to the best
health care regardless of their geographical location.
This vision centres on the realization that knowledge
must travel and that the patient should be able to stay in
Fig. 1 Goals of the European Reference Networks (ERNs). The Rare Disease Specific European Reference Networks (ERNs) are a project set up by
the European Union to ensure more equitable care across Europe by creating networks for virtual expert consultation, knowledge generation and
knowledge dissemination (Source: European Reference Network Brochure)
Fig. 2 Governance structure. ERN RARE-LIVER comprises a network board and a management board directed by the network coordinator
(currently Prof. Ansgar Lohse). The operational arm of the network is supported by three disease pillars. Pillar 1: Autoimmune liver disease. Pillar 2:
Metabolic, Biliary atresia and related diseases and Pillar 3: Structural liver disease. Each pillar is directed by a clinical committee and is made up by
experts from the health care professionals and patient advocates
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his/her own healthcare environment. Locally applied ex-
pert knowledge not only directly benefits patients, but it
also aids in dissemination of knowledge to local health-
care professionals and helps expert centres because they
get access to patients and their disease behaviour which
was impossible to get otherwise.
An account of the foundation and the set goals of the
ERN RARE-LIVER was published last year and the net-
work broadly formulated five goals (Fig. 3) [3]. This pos-
ition paper summarizes the achievements of the first
year and plots the route for the near future for ERN
RARE-LIVER, as discussed during a strategy meeting
that took place 27 and 28 February 2018 in Nijmegen,
the Netherlands. This was the 2nd meeting of the net-
work after the inception meeting that took place on
April 21, 2017 at the occasion of the European Associ-
ation for the Study of the Liver (EASL) International
Liver Congress in Amsterdam, the Netherlands.
Achievements
The focus of Year 1 of the ERN RARE-LIVER was to get
the organisational structures in place and secure funding
for an elementary, yet efficient, framework. The map for
the year ahead is to move from idea and governance
structure to a lively and vibrant organisation that actu-
ally starts to deliver: making a difference for patients.
The network achieved to establish a governance
framework and put a number of monitoring systems in
place to gauge success such as a risk registry and a qual-
ity control database. A very important step entailed the
survey of guidelines. ERN RARE-LIVER operates closely
in cooperation with European Society for Paediatric
Gastroenterology Hepatology and Nutrition (ESPHGAN)
and EASL and both organisations are committed to as-
sist physicians and other health care providers as well as
patients and those interested in the clinical decision-
making process by describing a range of generally ac-
cepted approaches for the diagnosis, treatment and pre-
vention of complication of specific liver diseases. The
data are critical to perform a gap analysis and identify
disorders / clinical situations that are in need of a
guideline.
Plans & goals
The plans for the near future for the ERN RARE-LIVER
fall in 3 categories.
Things we have to do
As ERN we will have to report progress on the outcome
parameters. To do so we will have to utilise the ap-
proved platforms such as the clinical patient manage-
ment system (CPMS). In order to achieve a better reach
in the European Union we must support new members.
Things we need to do
The gap analysis is needed to identify clinical areas in
need of guidelines or standards. This requires close
collaboration with professional organisation such as
EASL and ESPGHAN and other stakeholders [4]. We
will need to participate in tele-boards to really act as
a network of experts. A fine example comes from the
Dutch Pancreatitis Study Group who has launched an
online nationwide, multidisciplinary expert panel for
clinicians treating patients with acute necrotizing pan-
creatitis. This panel helps in clinical decision making
and has proved to be an accessible and valuable tool
for treating clinicians [5].
Fig. 3 Goals of the ERN RARE-LIVER
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Things we want to do
ERN acts as a marketplace which we want to populate
with clinicians interested in rare liver diseases. It offers
us with an opportunity to meet and interchange with
other professionals who have a shared interest in rare
liver diseases. In order to improve clinical care we want
to use the ERN as a network to facilitate, and direct clin-
ical trials at a European scale. The patient advocates in
our ERN are available to assist health care professionals
where needed. Parallel to the activities of the health care
professionals, they will focus on both training the patient
advocacy community as well as incorporating the pa-
tient’s voice in the health care professionals’ trainings.
Lastly, we are responsible for the clinicians of the future
and we need to educate and train those clinicians who
are able to provide excellent clinical care for the patients
of tomorrow.
Healthcare
The Clinical Patient Management System (CPMS) is es-
sential for interaction between healthcare professionals
and experts on clinical decision making, and was pro-
vided by the European Union to all ERNs. CPMS sup-
ports online multidisciplinary meetings (tele-boards) to
discuss patients with diagnostic or therapeutic dilemmas
in need for expert consultation. CPMS offers the oppor-
tunity to upload and share clinical data of patients and
pictures such as histological slides or Magnetic Reson-
ance Cholangio-Pancreaticography images. Importantly,
this is fully in line with European data protection law.
For example, a much debated issue during CPMS con-
sultations revolves around AIH patients who have failed
standard treatment and are in need of second or third
line therapy [6, 7]. There is a wide variation in the
management of difficult-to-treat AIH patients and al-
though good quality evidence is lacking, there is con-
siderable experience with different second and third
line treatment at different ERN RARE-LIVER centres
[8]. Tele-boards via CPMS and thereby expert con-
sensus assist enormously in the clinical management
of these patients [9].
In addition, CPMS is open to experts and advice-
seeking health care providers outside ERN RARE-
LIVER. It is possible to bring a difficult case to the ex-
pert panel via guest accounts to CPMS, even if the
health care provider is not affiliated with a specialist
centre of the ERN. For technical support, appointing to
the experts in the field and to provide assistance wher-
ever possible, a CPMS helpdesk has been installed by
ERN RARE-LIVER at the University Medical Centre
Hamburg-Eppendorf, Germany (CPMS.rareliver@uke.
de). In addition, the EU (European Union) and the soft-
ware provider of CPMS assure constant updates of
CPMS, to simplify the access process, improve
workflows and address needs of customization for the
respective ERN.
Transitional care
Transitioning adolescents and young adults with chronic
rare liver diseases can be complex. [10] There is no uni-
form model for successful transition, but expert opinion
suggests that a transition program enabling an increas-
ing responsibility for health management is important.
Expert recommendations support a transition process
that starts in early adolescence, and provides continuous
guidance and support. An excellent transition process al-
lows for care opportunities with patients and caregivers,
with the patient alone and between paediatric and adult
professionals. We consider transition of care as a unique
opportunity for ERN RARE-LIVER as the model that
will be designed will benefit children with and without
rare liver disorders but has the added benefit to bring
paediatric and adult hepatologists closer together to im-
prove this shortcoming that is also seen as problematic
by patients and patient organizations. Specifically, it is
our ambition to establish continuity-of-care pathways
from paediatric to adult care in all ERN centres within
the next two years. This should include the parents, who
often feel lost when their child transitions to adult hepa-
tology. Every child should be able to chart their individ-
ual transition to adult care.
Outcome monitoring
Registries may be the answer to the lack of solid evi-
dence in the field of rare liver disease [11]. By definition,
a registry is an organized system that uses observational
study methods to collect existing or uniform clinical
data from individual patients. A registry offers a unique
opportunity to conduct research on populations and
conditions that are not generally studied in clinical trials,
yet are important to clinical decision-makers. This is the
reason why a prospective online registry has been devel-
oped by members of the ERN RARE-LIVER. We aim to
include incident patients with a rare liver disease seen in
one of the expert centres. In addition, we will include
patients entered through CPMS who will be discussed
during the tele-boards. Three benefits will emanate from
this registry. In the first place, this registry will be used
to assess quality aims that are set by each of the pillars.
This will allow close monitoring of the quality aims and
goals that have been set, by us, as ERN RARE-LIVER.
Good examples for quality aims are: > 70% of patients
achieve remission within 12 months of AIH onset, > 90%
of primary PSC and PBC patients should have been
queried about pruritus, and > 90% of PBC patients
should receive the correct ursodeoxycholic acid dosage.
For cystic liver diseases, we aim to include all new pa-
tients in the registry and enable integration with the
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previously established International PLD Registry [11].
From a research perspective, benefits of a prospective
registry are that we might measure the natural clinical
history as well as clinical effectiveness and provide fol-
low up for delayed or long-term benefits or harm. Last
but not least, the patient will benefit from the expertise
and gains access to proper care. The ultimate goal is to
improve quality of care for rare liver diseases. This is
done by measuring what we do and what impact that
has on disease outcomes.
The EU General Data Protection Regulation (GDPR) is
a new European law, effective 25 May 2018 that protects
and empowers EU citizens data privacy and reshapes the
way organizations across the region approach data priv-
acy [12]. The conditions for consent have been strength-
ened, and consent forms must be clear and formulated
in easily accessible terms and it must be as easy to with-
draw consent as it is to give it. The prospective registry
set up by the ERN, abides by the new privacy legislation
and can be used in any EU member state (Fig. 4).
Clinical care
As a consortium of the European experts on the subject
of rare liver disease, the ERN sees it role fit to create
position papers on subjects within rare liver disease
where evidence is lacking, but advice for patients and
clinicians is necessary. The gap analysis – in cooperation
with patient organizations - will assist us in order to
identify uncovered areas (which are likely to exist in rare
liver disease). Subsequently we would target a number of
areas where the development and implementation of
standardised protocols and guidelines would most bene-
fit patients with rare liver diseases. One example that is
sought after by patients is a position paper on pregnancy
in autoimmune liver disease.
The ERN will start to design a plan for guidelines and
care pathways that can be made in association with
EASL and ESPHGAN. This set of guidelines is key to
the promise to offer patients the same chance for diag-
nosis and adequate treatment throughout Europe. In
addition to developing guidelines, we are now looking at
those already in existence; how we can endorse their
content and how we can ensure that they reach the wid-
est possible audience. We are designing a procedure that
will help to endorse existing guidelines in collaboration
with EASL and ESPGHAN in order to get the widest
reach as possible. A key task of the ERN RARE-LIVER
network will be the development of a care pathway to
accompany these guidelines, which will outline the key
steps in management and facilitate their delivery in prac-
tice across Europe [13].
We note that not all rare liver diseases are covered by
our ERN. We are starting to map the route towards ex-
pansion of the number of diseases. This will be driven
Fig. 4 International registry data protection structure. We present the digital structure of the international registry, which will be used for
outcome monitoring of quality aims and research questions. Each participating centre will retain ownership of the data. All data is uploaded
pseudonymized. Privacy is secured according to German laws and guidelines, thus the system can be used Europe-wide. The versatile
user-interface of the registry will run on Castor EDC (CIWIT B.V., Amsterdam, the Netherlands)
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by the need of patients. For example, autosomal reces-
sive polycystic kidney disease (ARPKD) is a disorder that
presents in childhood with predominantly extra-hepatic
features such as renal impairment and lung hypoplasia,
only when children reach adulthood, liver related com-
plications as a result of fibrosis formation start to ensue.
Patient representatives have asked us to put this on our
radar.
Teaching and training
ERN RARE-LIVER will identify gaps within the current
training of adult and paediatric hepatologists and aims
to develop strategies to provide education, training and
continuing professional development to address short-
comings. As such ERN RARE-LIVER strives as focal
point for medical training and research, for both health-
care professionals and patient advocates. Few patients
with a rare liver condition currently benefit from effect-
ive or curative therapies, and many do not have a defin-
ite diagnosis. Many have little easy-understandable
knowledge of their disease in their native language and
patient advocates can be helpful to fill that hole. Inter-
weaving healthcare and innovative research helps to ad-
dress this issue and is close to the heart of ERN. The
combined expert centres have a large repository of
teaching materials. The remit of ERN RARE-LIVER is to
extend the reach of teaching documents. This is relevant
for both patients and clinicians. The proposed ideas are:
listing all the materials on the ERN RARE-LIVER web-
site for easy access, creating e-learning modules, includ-
ing content in curricula for fellows and exchange of
knowledge between centres, for example with Marie
Curie fellowships. In particular, ERN will also be produ-
cing patient summaries of guidelines, with the goal that
patients can be offered a lay version, available in their
native language. This will contribute to the goals set for
the ERN. Finally, we plan to populate an ERN School for
Rare Liver Diseases which helps to inform the wider sci-
entific community about these diseases.
Research
Research is close to the heart of the experts who popu-
late ERN RARE-LIVER. Innovative research has the po-
tential to change the lives of patients by providing them
with new tools to improve diagnosis, care and even cure.
Rare liver diseases are ill researched and most patient
oriented studies are observational by nature. While this
yields very relevant information about disease and/or
disease behaviour it does not allow study of the effect of
interventions. This requires well designed clinical trials.
Biomedical industry has started to develop interest in
rare liver disorders and the recent POISE trial examining
the effect of obeticholic acid in PBC is a good example
of how collaboration between academia and industry
can pave the way towards innovative research [14]. ERN
has a vested interest in supporting investigator initiated
clinical trials. ERN RARE-LIVER provides researchers
with the indispensable network and permits access to
patients. We identified the need for a research strategy
group or desk consisting of a representation of liver ex-
perts who can assist and direct us which research strat-
egy to adopt (and support) and which applications we
want to support.
Expansion
ERN RARE-LIVER was initiated by a core group of ex-
perts with an interest in rare liver diseases. In order to
get the best reach and traction in the European Union,
expansion of the number of sites is mandatory. The way
forward is to expand the ERN by including new expert
centres, in particular from those coming from countries
that have not been included before. There are different
forms of membership within the ERN networks: full
membership, and more importantly, affiliated or collab-
orative partnership. Centres that aspire to membership
or partnership must bring a true added value to the ERN
and must have documented expertise in at least one of
the diseases that the ERN in question covers. Other cri-
teria that have been set by ERN RARE-LIVER are: a
minimum of 2 active CPMS users per centre, contribu-
tion of 5 CPMS cases per year and to enter at least 30
patients into the R-LIVER registry.
Full membership
Full Members have the full voting right for ERN internal
decisions, they get access to funding or resources linked
to ERN and they get access to a full user account for
CPMS. Only centres from the EU can apply. There are
two steps that have to be taken for full membership of an
ERN; relevant hyperlinks to WebPages and contact infor-
mation have been added to Additional file 2. First, support
of an applying centre’s national health ministry is required.
The “Board of Member States” (BoMS) is the oversight
body for the EU and has representatives from all the
health ministries for member states; the respective na-
tional board member should be the first contact (Add-
itional file 2). The second step comprises the completion
of an assessment process which includes a form, a self-
assessment and supporting data and potentially a site
audit. The final approval will take place by the BoMS. At
present, the assessment process is still being finalized,
however, the need for national approval will remain. So if
you are considering full membership, seeking this ap-
proval is a concrete step you can take now.
Affiliated partnership
In order for ERNs to deliver genuine added value to all
European Union Member States, legislation makes
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provision for ‘Member States which do not have represen-
tation from a member within an approved ERN’ to partici-
pate through affiliated partnerships. Centres from a
member state that does not currently have a full member
and which are interested in Affiliated Partnership must be
designated by their member state and need to contact the
BoMS representative in the first instance. If the country
has a full member then options are either Full Member-
ship or Collaborative Partnership. Applications can be
handed in now until the opening of the call for full mem-
bers. Application forms are provided by the BoMS.
Collaborative partnership
The collaborative partnership is a looser form of mem-
bership which does not bring ERN Centre Status but al-
lows members to develop links with some of the
activities of the ERN. Centres from the EU, European
Economic Area, and non-EU can apply. In addition, both
centres from member states with or without a full mem-
ber can apply as a collaborative partner of the ERN. This
does not entail an EU process and is managed by the
ERN RARE-LIVER itself. The ERN provides its own Col-
laborative Partnership form to centres interested in join-
ing. Centres can apply at any time. Collaborative
Partners have no voting right for ERN internal decisions,
they do not get access to funding or resources linked to
ERN and they need a guest user account for using
CPMS.
The role of patient organizations
As patient organizations are central to the concept of
ERNs, they will shape ERN RARE-LIVER together with ex-
perts from the field as they are uniquely positioned to
identify the unmet needs among patients. Each pillar has 2
patient advocates as member of the clinical committee in
order to represent, inform and direct. Patient advocates
come from 37 patient groups and our effort is key to bring
patient organizations together, which enhances cross
-fertilization. The patient organizations play an essential
role in informing the public and most importantly patients
in Europe. Indeed, clear communication is key to improv-
ing healthcare. Patient advocates receive training through
ERN activities through workshops. Eurordis has also of-
fered them a broad range of training, including webinars,
meetings, capacity training, Summer school and Winter
School. In effect, clinicians teach patients and vice versa.
For example, patient group representatives can join courses
to learn more about their disease and other rare liver dis-
eases. We think that the role of the patients in setting an
agenda for research, guidelines and information sources is
central to the idea of ERN. One notable achievement is the
patient involvement in the recent PBC clinical practice
guideline of EASL where patients helped to identify import-
ant areas for improvement of liver care and shift focus to
symptoms that are underappreciated, such as fatigue in
PBC [15]. As patient organizations are also increasingly
committed in research projects, they emphasized that re-
searchers must pay serious attention to patient engagement
and that there is ample room for improvement. Patients
need mentoring and coaching and expert patients/carers
need to be enabled. Patients are often not unwilling, but
need more assistance in order to deliver.
Conclusions
This meeting was the first in its kind and met with the
expectations. ERN RARE-LIVER is established as a
Fig. 5 Seeking contact with ERN RARE-LIVER
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group and the investments put into collaboration starts
to pay off. The year ahead will be the start of a true inte-
gral cooperation between many expert centres in Europe
with a clear goal to improve healthcare, research and
education related to rare liver diseases.
Health care providers who are interested in joining
ERN RARE-LIVER can find more information on the
website: ‘https://www.rare-liver.eu/’, in Fig. 5, and
Additional file 2.
Additional files
Additional file 1: Collaborative Centres of the ERN RARE-LIVER (April
2019). (DOCX 46 kb)
Additional file 2: Important links (ERN RARE-LIVER). (DOCX 15 kb)
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